应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
已收盘 12-19 16:08:47
4.590
-0.050
-1.08%
最高
4.600
最低
4.430
成交量
150.35万
今开
4.590
昨收
4.640
日振幅
3.66%
总市值
37.50亿
流通市值
37.50亿
总股本
8.17亿
成交额
677.69万
换手率
0.18%
流通股本
8.17亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
欧康维视生物回购31万股 总金额141万港元
财中社 · 20:54
欧康维视生物回购31万股 总金额141万港元
欧康维视生物-B(01477)12月19日斥资141万港元回购31.05万股
智通财经 · 20:47
欧康维视生物-B(01477)12月19日斥资141万港元回购31.05万股
歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股
智通财经 · 18:45
歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股
中生制药(01177.HK)将为创新药递交ASPS适应症上市申请
阿斯达克财经 · 16:39
中生制药(01177.HK)将为创新药递交ASPS适应症上市申请
欧洲医疗保健股前景复杂 美国政策及新药试验结果成关键
智通财经 · 14:48
欧洲医疗保健股前景复杂 美国政策及新药试验结果成关键
歌礼制药-B(01672)下跌11.27%，报2.52元/股
金融界 · 13:58
歌礼制药-B(01672)下跌11.27%，报2.52元/股
港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.
美港电讯 · 10:57
港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.
歌礼制药减重药物ASC47联合用药显著优于单药疗法
财中社 · 09:43
歌礼制药减重药物ASC47联合用药显著优于单药疗法
歌礼制药-B盘中异动 股价大跌5.28%
市场透视 · 09:32
歌礼制药-B盘中异动 股价大跌5.28%
再生元制药下跌1.21%，报731.041美元/股
金融界 · 02:44
再生元制药下跌1.21%，报731.041美元/股
歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效
阿斯达克财经 · 01:20
歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效
Bioage Labs宣布与诺华制药(NVS.N)开展多年合作，以发现治疗与年龄相关疾病和病症的新靶点。
美港电讯 · 12-18 22:04
Bioage Labs宣布与诺华制药(NVS.N)开展多年合作，以发现治疗与年龄相关疾病和病症的新靶点。
歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果
智通财经 · 12-18 21:32
歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果
欧康维视生物回购9500股股份 总金额4.5万港元
财中社 · 12-18 20:37
欧康维视生物回购9500股股份 总金额4.5万港元
欧康维视生物-B(01477)12月18日斥资4.46万港元回购9500股
智通财经 · 12-18 18:41
欧康维视生物-B(01477)12月18日斥资4.46万港元回购9500股
中生制药(01177.HK)非小细胞肺癌放化疗后巩固治疗药物III期研究取得阳性结果 将就适应症提上市申请
阿斯达克财经 · 12-18 17:05
中生制药(01177.HK)非小细胞肺癌放化疗后巩固治疗药物III期研究取得阳性结果 将就适应症提上市申请
歌礼制药：恒指收涨 0.83% 生物医药走强
和讯网 · 12-18 16:33
歌礼制药：恒指收涨 0.83% 生物医药走强
港股收盘，恒指收涨0.83%，恒生科技指数收涨1.82%，生物技术板块午后走强，歌礼制药(01672.HK)收涨19.33%，药明生物(02269.
美港电讯 · 12-18 16:10
港股收盘，恒指收涨0.83%，恒生科技指数收涨1.82%，生物技术板块午后走强，歌礼制药(01672.HK)收涨19.33%，药明生物(02269.
歌礼制药－Ｂ(01672)股价大幅上升18.908%，现价港币$2.83
阿斯达克财经 · 12-18 15:59
歌礼制药－Ｂ(01672)股价大幅上升18.908%，现价港币$2.83
港股生物技术板块尾盘走强，歌礼制药涨超15%
每日经济新闻 · 12-18 15:37
港股生物技术板块尾盘走强，歌礼制药涨超15%
加载更多
公司概况
公司名称：
欧康维视生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。
发行价格：
--
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":4.59,"timestamp":1734595727013,"preClose":4.64,"halted":0,"volume":1503500,"delay":0,"floatShares":817000000,"shares":817000000,"eps":-0.627564,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.05,"latestTime":"12-19 16:08:47","open":4.59,"high":4.6,"low":4.43,"amount":6776932,"amplitude":0.036638,"askPrice":4.59,"askSize":500,"bidPrice":4.51,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.5280155505668652,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1594310400000,"adjPreClose":4.64,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":1.504046,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2492127682","title":"欧康维视生物回购31万股 总金额141万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127682","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492127682?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:54","pubTimestamp":1734612849,"startTime":"0","endTime":"0","summary":"财中社12月19日电欧康维视生物-B（01477）发布公告，2024年12月19日，公司回购股份31万股，回购金额为141万港元。根据回购授权的决议，公司可回购的股份总数为6936万股，已回购股份1649万股，占回购授权决议通过时已发行股份的2.3767%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412193273499945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2492112245","title":"欧康维视生物-B(01477)12月19日斥资141万港元回购31.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112245","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492112245?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:47","pubTimestamp":1734612472,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2024年12月19日该公司斥资141万港元回购31.05万股，回购价格为每股4.460-4.592港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2492128831","title":"歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492128831","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492128831?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:45","pubTimestamp":1734605117,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2024年12月19日，该公司斥资63.44万港元回购26万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","01672","BK1191","BK1161","BK1515"],"gpt_icon":0},{"id":"2492145201","title":"中生制药(01177.HK)将为创新药递交ASPS适应症上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492145201","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492145201?lang=zh_cn&edition=full","pubTime":"2024-12-19 16:39","pubTimestamp":1734597540,"startTime":"0","endTime":"0","summary":"中生制药公布，集团自主研发的1类创新药贝莫苏拜单抗注射液联合盐酸安罗替尼胶囊，已向中国药监局药品审评中心就新增晚期腺泡状软组织肉瘤适应症的上市申请进行沟通，并获得CDE书面同意提交上市申请。集团将于近期递交上市申请。ASPS是安罗替尼即将申报上市的第12个适应症、贝莫苏拜单抗即将申报上市的第5个适应症，有望为ASPS患者带来新的治疗选择。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405300&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06978","BK1589","01477","01177","BK1161","BK1515","BK1191","159992","BK1521"],"gpt_icon":0},{"id":"2492114566","title":"欧洲医疗保健股前景复杂 美国政策及新药试验结果成关键","url":"https://stock-news.laohu8.com/highlight/detail?id=2492114566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492114566?lang=zh_cn&edition=full","pubTime":"2024-12-19 14:48","pubTimestamp":1734590891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在2024年最后几个月跌下高位后，欧洲医疗保健股在新的一年里面临着美国政治和高风险新药试验结果的风险。而在9月时，医疗保健还是今年以来欧洲股市中表现最好的板块。对欧洲医疗保健股的投资者来说，关键在于美国医疗保健政策的明确性。欧洲医疗保健类股此前之所以涨势强劲，部分原因在于它们具有抵御欧洲经济低迷背景的吸引力，而对减肥药的狂热也推高了估值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2492111990","title":"歌礼制药-B(01672)下跌11.27%，报2.52元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492111990","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492111990?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:58","pubTimestamp":1734587923,"startTime":"0","endTime":"0","summary":"12月19日，歌礼制药-B(01672)盘中下跌11.27%，截至13:58，报2.52元/股，成交1578.12万元。歌礼制药有限公司是一家创新研发驱动型生物科技公司，主要从事病毒性疾病、非酒精性脂肪性肝炎和肿瘤等三大医疗领域的新药研发、生产和商业化。该公司在浙江绍兴滨海新城拥有约17,000平方米的生产基地，设计年产能为1.3亿片，拥有多款在研药物并已取得药品生产许可证。截至2023年年报，歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/19135846577538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01477","BK1515","BK1191","BK1574","01672"],"gpt_icon":0},{"id":"2492919919","title":"港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492919919","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492919919?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:57","pubTimestamp":1734577079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","02898","01672","01477","02105","BK1515","BK1191","02257","09939","BK1574","159718"],"gpt_icon":0},{"id":"2492719347","title":"歌礼制药减重药物ASC47联合用药显著优于单药疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2492719347","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492719347?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:43","pubTimestamp":1734572616,"startTime":"0","endTime":"0","summary":"财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412193272970722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","01672","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2492160043","title":"歌礼制药-B盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492160043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492160043?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:32","pubTimestamp":1734571945,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘09时32分，歌礼制药-B股票出现波动，股价急速下跌5.28%。截至发稿，该股报2.690港元/股，成交量40.5万股，换手率0.04%，振幅5.28%。资金方面，该股资金流入50.617万港元，流出23.88万港元。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.64%。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093225984cbfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093225984cbfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","01672","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2492137545","title":"再生元制药下跌1.21%，报731.041美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492137545","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492137545?lang=zh_cn&edition=full","pubTime":"2024-12-19 02:44","pubTimestamp":1734547459,"startTime":"0","endTime":"0","summary":"12月19日，再生元制药(REGN)盘中下跌1.21%，截至02:44，报731.041美元/股，成交2.12亿美元。财务数据显示，截至2024年09月30日，再生元制药收入总额104.13亿美元，同比增长7.54%；归母净利润34.95亿美元，同比增长25.09%。大事提醒：12月17日，再生元制药获加通贝祥首次给予评级Hold，目标价165美元。2025年2月7日，再生元制药将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/19024446565790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2492130139","title":"歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2492130139","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492130139?lang=zh_cn&edition=full","pubTime":"2024-12-19 01:20","pubTimestamp":1734542400,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ(01672.HK) 公布，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖(DIO)小鼠模型研究中显示令人鼓舞的疗效。ASC47是歌礼自主研发的脂肪靶向，具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。ASC47当前正在澳洲进行肥胖症患者临床试验，IIa期研究顶线数据预计将于2025年第二季度公布。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405066/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01477","BK1515","BK1191","BK1574","01672"],"gpt_icon":0},{"id":"2492275186","title":"Bioage Labs宣布与诺华制药(NVS.N)开展多年合作，以发现治疗与年龄相关疾病和病症的新靶点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2492275186","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492275186?lang=zh_cn&edition=full","pubTime":"2024-12-18 22:04","pubTimestamp":1734530683,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00BFTCPJ56.SGD","NVS","01477","LU0211331839.USD","IE0002141913.USD","BK4007","BK1574","IE00BJJMRZ35.SGD","BK4578","BK4588","IE00B2B36J28.USD","BK1191","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4532","IE0009355771.USD","BK4585"],"gpt_icon":0},{"id":"2492185407","title":"歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185407","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492185407?lang=zh_cn&edition=full","pubTime":"2024-12-18 21:32","pubTimestamp":1734528764,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中显示出令人鼓舞的疗效。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。常规剂量ASC47使肌肉总量增加5.8%，而司美格鲁肽使肌肉总量减少9.3%。低剂量ASC47联合用药1优于司美格鲁肽单药疗法，联合用药使体重下降36.2%，司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","01672","BK1191","BK1161","BK1515"],"gpt_icon":0},{"id":"2492795188","title":"欧康维视生物回购9500股股份 总金额4.5万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492795188","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492795188?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:37","pubTimestamp":1734525436,"startTime":"0","endTime":"0","summary":"财中社12月18日电欧康维视生物-B（01477）发布公告，2024年12月18日，公司回购股份9500股，回购金额为4.5万港元。根据回购授权的决议，公司可回购的股份总数为6936万股，已回购股份1617万股，占回购授权决议通过时已发行股份的2.3319%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272266545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2492906579","title":"欧康维视生物-B(01477)12月18日斥资4.46万港元回购9500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492906579","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492906579?lang=zh_cn&edition=full","pubTime":"2024-12-18 18:41","pubTimestamp":1734518513,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2024年12月18日，该公司斥资4.46万港元回购9500股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2492972491","title":"中生制药(01177.HK)非小细胞肺癌放化疗后巩固治疗药物III期研究取得阳性结果 将就适应症提上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2492972491","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492972491?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:05","pubTimestamp":1734512700,"startTime":"0","endTime":"0","summary":"集团已与中国国家药品监督管理局药品审评中心就该适应症的上市申请进行沟通，并获得CDE书面同意提交上市申请。集团将于近期递交上市申请。同步/序贯放化疗后未进展的、局部晚期/不可切除的NSCLC的巩固治疗是安罗替尼即将申报上市的第11个适应症、贝莫苏拜单抗即将申报上市的第4个适应症。(港股报价延迟最少十五分钟。沽空资料截至 2024-12-18 16:25。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1405004&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","01477","BK1589","BK1191","BK1521","BK1515","BK1574"],"gpt_icon":0},{"id":"2492901978","title":"歌礼制药：恒指收涨 0.83% 生物医药走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901978","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901978?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:33","pubTimestamp":1734510825,"startTime":"0","endTime":"0","summary":"【港股收评：恒指午后再度冲击两万大关未 生物医药板块走强】恒指在录得三连阴后，早间高开反弹，之后震荡低走。午后伴随 A 股冲高，其再度测试两万点大关，未突破后回落，维持水上震荡。截至今日收盘，恒生指数收涨 0.83%，报 19864.55 点。恒生科技指数收涨 1.82%，报 4468.85 点，恒指大市成交额为 1075.41 亿港元。盘面上，科网股表现强势，汽车股、生物医药股回暖造好，航空股、煤炭股午后跌幅扩大。个股方面，歌礼制药收涨 19.33%，国联证券收跌 3.94%，理想汽车收涨 5.45%，小鹏汽车收涨 4.05%，中国神华收跌 1.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191138ab81a956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191138ab81a956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02833","01477","HSI","BK1191","BK1161","MCHmain","BK1515","513600","BK1574","01672","HHImain"],"gpt_icon":0},{"id":"2492583979","title":"港股收盘，恒指收涨0.83%，恒生科技指数收涨1.82%，生物技术板块午后走强，歌礼制药(01672.HK)收涨19.33%，药明生物(02269.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492583979","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492583979?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:10","pubTimestamp":1734509424,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1521","LU0516422366.SGD","07226","HSI","MCHmain","513600","LU1688375341.USD","HHImain","LU0043850808.USD","LU0359201612.USD","HSImain","BK1610","LU0307460666.USD","LU0039217434.USD","IE00B0JY6N72.USD","LU0516423174.USD","LU0572944931.SGD","LU0708995583.HKD","LU0823426480.USD","LU0327786744.USD","02833","LU0516422952.EUR","BK1576","LU0181495838.USD","02269","LU1880383366.USD","LU0140636845.USD","01672","LU0320764599.SGD","LU2039709279.SGD","LU1794554557.SGD","BK1141","HSCEI","BK1515","LU0051755006.USD","BK1589","LU0979878070.USD","LU1242518857.USD","01477","MHImain","LU0348735423.USD","LU0417516902.SGD","LU0359202008.SGD","LU1242518931.SGD","SG9999002562.SGD","LU0326950275.SGD","YANG","LU1720050803.USD","HSTECH","LU0516422440.USD"],"gpt_icon":0},{"id":"2492979525","title":"歌礼制药－Ｂ(01672)股价大幅上升18.908%，现价港币$2.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2492979525","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492979525?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:59","pubTimestamp":1734508740,"startTime":"0","endTime":"0","summary":"[上升股]歌礼制药－Ｂ(01672) 股价在下午03:59比前收市价大幅上升18.908%，现股价为港币$2.83。至目前为止，今日最高价为$2.84，而最低价为$2.4。总成交量为1千万股，总成交金额为港币$2.713千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2412181710/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","01477","BK1515","BK1191","01672","BK1161"],"gpt_icon":0},{"id":"2492766509","title":"港股生物技术板块尾盘走强，歌礼制药涨超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492766509","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492766509?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:37","pubTimestamp":1734507426,"startTime":"0","endTime":"0","summary":"每经AI快讯，港股生物技术板块尾盘走强，歌礼制药(01672.HK)涨超15%，圣诺医药(02257.HK)涨超9%，再鼎医药(09688.HK)、三叶草生物(02197.HK)等跟涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412183272069664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272069664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01672","01477","BK1515","BK1191","BK1161","YANG","BK1574","HSCEI","HSTECH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0664},{"period":"1month","weight":-0.1179},{"period":"3month","weight":0.0243},{"period":"6month","weight":-0.3216},{"period":"1year","weight":-0.3075},{"period":"ytd","weight":-0.3054}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.137321},{"month":2,"riseRate":0.25,"avgChangeRate":-0.072355},{"month":3,"riseRate":0.5,"avgChangeRate":0.043389},{"month":4,"riseRate":0.25,"avgChangeRate":0.004659},{"month":5,"riseRate":0.5,"avgChangeRate":0.068025},{"month":6,"riseRate":0.75,"avgChangeRate":0.066459},{"month":7,"riseRate":0.5,"avgChangeRate":-0.028018},{"month":8,"riseRate":0.4,"avgChangeRate":-0.050881},{"month":9,"riseRate":0.2,"avgChangeRate":-0.087999},{"month":10,"riseRate":0.2,"avgChangeRate":-0.144034},{"month":11,"riseRate":0.4,"avgChangeRate":0.008996},{"month":12,"riseRate":0.6,"avgChangeRate":0.094624}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}